Thu, Aug 21, 2014, 3:48 PM EDT - U.S. Markets close in 12 mins.

Recent

% | $
Quotes you view appear here for quick access.

Nokia Corporation Message Board

roosterly9 25 posts  |  Last Activity: 18 hours ago Member since: Nov 5, 2003
  • Isis Pharmaceuticals Inc. (ISIS), a maker of gene therapy treatments, may seek to expand use of an experimental drug targeting triglycerides to fight heart disease, a move an analyst says could add $2 billion in sales.

    The drug targets the APOC3 gene and is now aimed solely at a rare disease that’s linked to diabetes and pancreatitis and affects about 5,000 people. Two studies this week, however, have also tied the gene to lower risk of heart disease, an illness that kills 600,000 people yearly, a much larger target.

    The research, done independently of Isis, was highlighted in the New England Journal of Medicine. It may open a new window of opportunity for Isis once the drug, called ISIS-APOCIIIRx and heading to final testing, is approved and may spark interest from potential acquirers, analysts said.

    “We’re weighing how we want to take full advantage of this breakthrough, and as we do that we have to consider the potential broader development of the follow on product,” Isis Chief Executive Officer Stanley Crooke said by telephone. “We have a great deal of licensing interest for this drug.”

    In the New England Journal of Medicine studies, mutations in the APOC3 gene decreased the risk of a heart attack by about 40 percent. Adding value to the current drug could open the company up to a takeover bid, said Joshua Schimmer, a Piper Jaffray & Co. analyst in New York.

    The Carlsbad, California-based company has “a super deep pipeline, and none of it is adequately reflected in the stock price,” Schimmer said in a telephone interview. “At this valuation, it would be ripe for a hostile event.”

    32 products

    Isis, founded by by Crooke in 1989, has grown to a $4.09 billion market capitalization and a pipeline of 32 products. Today the stock rose 3.2 percent to $34.82 at 4 p.m. New York time. It has dropped 41 percent since reaching a record high of $59 on February 21, compared with a 6.8 percent drop

  • Reply to

    CYTR HAS NO REVENUES AND MASSIVE MARKET CAP

    by osprey.watch3 Jun 17, 2014 9:29 PM
    roosterly9 roosterly9 Jun 17, 2014 10:32 PM Flag

    Are you stupid or what, you call under $300 million market cap, massive? Maybe you don't know what market cap means. didn't one biotech with no revenue just got bought out for $3.8 Billion?

  • ENTA has much more advanced drug, near approval, selling at $41.5.

  • This despite the fact that ENTA's drug is rear approval, and IDIX is in 2nd inning on their drug.

  • roosterly9 roosterly9 Jun 9, 2014 9:02 AM Flag

    not $2.5 billion, $3.8 Billion, ENTA has a drug in verge of approval, and same valuation as IDIX will put ENTA at $200

NOK
8.24+0.11(+1.41%)3:48 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.